Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53

Molecular and Cellular Biology

Volumn 19, Issue 5, 1999, Pages 3704-3713

  Blattner, Christine ^a   Sparks, Alison ^a   Lane, David ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; DACTINOMYCIN; DOUBLE MINUTE CHROMOSOME 2 PROTEIN; KINASE INHIBITOR DRB; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN P53; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

ARTICLE; DNA DAMAGE; DOUBLE MINUTE CHROMOSOME; HALF LIFE TIME; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SEQUENCE HOMOLOGY; ULTRAVIOLET IRRADIATION; X IRRADIATION;

RODENTIA;

EID: 0032939925     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.19.5.3704     Document Type: Article

References (61)

1. Barak, Y., T. Juven, R. Haffner, and M. Oren. 1993. Mdm2 expression is induced by wild type-p53 activity. EMBO J. 12:461-468.
2. Bartek, J., J. Bartkova, and J. Lukas. 1996. The retinoblastoma protein pathway and the restriction point. Curr. Opin. Cell Biol. 8:805-814.
3. Bartek, J., B. Vojtesek, R. J. A. Grand, P. H. Gallimore, and D. P. Lane. 1992. Cellular-localization and T-antigen binding of the retinoblastoma protein. Oncogene 7:101-108.
4. Blattner, C., E. Tobiasch, M. Litfin, H. J. Rahmsdorf, and P. Herrlich. 1999. DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation. Oncogene 18:1723-1733.
5. 4a. Blattner, C. Unpublished data.
6. Blaydes, J. P., V. Gire, J. M. Rowson, and D. Wynford-Thomas. 1997. Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2. Oncogene 14:1859-1868.
7. Bottger, A., V. Bottger, A. Sparks, W. L. Liu, S. F. Howard, and D. P. Lane. 1997. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7:860-869.
8. 6a. Bottger, A. Personal communication.
9. Boukamp, P., R. T. Petrussevska, D. Breitkreutz, J. Hornung, A. Markham, and N. E. Fusenig. 1988. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell-line. J. Cell Biol. 106:761-771.
10. Campanero, M. R., and E. K. Flemington. 1997. Regulation of E2F through ubiquitin-proteasome-dependent degradation: stabilization by the pRb tumor suppressor protein. Proc. Natl. Acad. Sci. USA 94:2221-2226.
11. Chen, J. D., V. Marechal, and A. J. Levine. 1993. Mapping of the p53 and Mdm-2 interaction domains. Mol. Cell. Biol. 13:4107-4114.
12. Chen, L. H., S. Agrawal, W. Q. Zhou, R. W. Zhang, and J. D. Chen. 1998. Synergistic activation of p53 by inhibition of Mdm2 expression and DNA damage. Proc. Natl. Acad. Sci. USA 95:195-200.
13. 1/S-regulatory genes. Mol. Cell. Biol. 15:4215-4224.
14. 1 arrest and apoptosis. Cancer Res. 54:1169-1174.
15. Field, S. J., F. Y. Tsai, F. Kuo, A. M. Zubiaga, W. G. Kaelin, D. M. Livingston, S. H. Orkin, and M. E. Greenberg. 1996. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 85:549-561.
16. Flemington, E. K., S. H. Speck, and W. G. Kaelin. 1993. E2F-1-mediated transactivation is inhibited by complex-formation with the retinoblastoma susceptibility gene-product. Proc. Natl. Acad. Sci. USA 90:6914-6918.
17. Florenes, V. A., G. M. Maelandsmo, A. Forus, A. Andreassen, O. Myklebost, and O. Fodstad. 1994. Mdm2 gene amplification and transcript levels in human sarcomas - relationship to the p53 gene status. J. Natl. Cancer Inst. 86:1297-1302.
18. Fort, P., L. Marty, M. Piechaczyk, S. Elsabrouty, C. Dani, P. Jeanteur, and J. M. Blanchard. 1985. Various rat adult tissues express only one major messenger-RNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acids Res. 13:1431-1442.
19. Freedman, D. A., and A. J. Levine. 1998. Nuclear export is required for degradation of endogenous p53 by Mdm2 and human papillomavirus E6. Mol. Cell. Biol. 18:7288-7293.
20. Grossman, S. R., M. Perez, A. L. Kung, M. Joseph, C. Mansur, Z. X. Xiao, S. Kumar, P. M. Howley, and D. M. Livingston. 1998. p300/Mdm2 complexes participate in Mdm2-mediated p53 degradation. Mol. Cell 2:405-415.
21. Gu, W., and R. G. Roeder. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595-606.
22. Hagemeier, C., A. Cook, and T. Kouzarides. 1993. The retinoblastoma protein binds E2F residues required for activation in-vivo and TBP binding in-vitro. Nucleic Acids Res. 21:4998-5004.
23. Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge. 1993. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.
24. Hateboer, G., R. M. Kerkhoven, A. Shvarts, R. Bernards, and R. L. Beijersbergen. 1996. Degradation of E2F by the ubiquitin-proteasome pathway: regulation by retinoblastoma family proteins and adenovirus transforming proteins. Genes Dev. 10:2960-2970.
25. Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
26. Helin, K. 1998. Regulation of cell proliferation by the E2F transcription factors. Curr. Opin. Genet. Dev. 8:28-35.
27. Helin, K., E. Harlow, and A. Fattaey. 1993. Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Mol. Cell. Biol. 13: 6501-6508.
28. Hengstermann, A., N. J. Whitaker, D. Zimmer, H. Zentgraf, and M. Scheffner. 1998. Characterization of sequence elements involved in p53 stability regulation reveals cell type dependence for p53 degradation. Oncogene 17:2933-2941.
29. Hofmann, F., F. Martelli, D. M. Livingston, and Z. Y. Wang. 1996. The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway. Genes Dev. 10:2949-2959.
30. Holmberg, C., K. Helin, M. Sehested, and O. Karlstrom. 1998. E2F-1-induced p53-independent apoptosis in transgenic mice. Oncogene 17:143-155.
31. Honda, R., H. Tanaka, and H. Yasuda. 1997. Oncoprotein Mdm2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:25-27.
32. Huang, Y. Y., T. Ishiko, S. Nakada, T. Utsugisawa, T. Kato, and Z. M. Yuan. 1997. Role for E2F is DNA damage-induced entry of cells into S phase. Cancer Res. 57:3640-3643.
33. Hunt, K. K., J. Deng, T. J. Liu, M. WilsonHeiner, S. G. Swisher, G. Clayman, and M. C. Hung. 1997. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res. 57:4722-4726.
34. Johnson, D. G., J. K. Schwarz, W. D. Cress, and J. R. Nevins. 1993. Expression of transcription factor E2F-1 induces quiescent cells to enter S-phase. Nature 365:349-352.
35. Kastan, M. B., Q. M. Zhan, W. S. Eldeiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein, and A. J. Fornace. 1992. A mammalian-cell cycle checkpoint pathway utilizing p53 and Gadd45 is defective in ataxiatelangiectasia. Cell 71:587-597.
36. Kowalik, T. F., J. DeGregori, G. Leone, L. Jakoi, and J. R. Nevins. 1998. E2F-1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ. 9:113-118.
37. Kowalik, T. F., J. Degregori, J. K. Schwarz, and J. R. Nevins. 1995. E2F-1 overexpression in quiescent fibroblasts leads to induction of cellular DNA-synthesis and apoptosis. J. Virol. 69:2491-2500.
38. Kubbutat, M. H. G., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387:299-303.
39. Kuerbitz, S. J., B. S. Plunkett, W. V. Walsh, and M. B. Kastan. 1992. Wild-type p53 is a cell-cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89:7491-7495.
40. Lu, X., and D. P. Lane. 1993. Differential induction of transcriptionally active p53 following UV or ionizing-radiation - defects in chromosome instability syndromes. Cell 75:765-778.
41. Maki, C. G., J. M. Huibregtse, and P. M. Howley. 1996. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 56:2649-2654.
42. Maltzman, W., and L. Czyzyk. 1984. UV irradiation stimulates levels of p53 cellular tumor-antigen in nontransformed mouse cells. Mol. Cell. Biol. 4:1689-1694.
43. Martin, K., D. Trouche, C. Hagemeier, T. S. Sorensen, N. B. LaThangue, and T. Kouzarides. 1995. Stimulation of E2F-11/DP-1 transcriptional activity by Mdm2 oncoprotein. Nature 375:691-694.
44. Midgley, C. A., C. J. Fisher, J. Bartek, B. Vojtesek, D. Lane, and D. M. Barnes. 1992. Analysis of p53 expression in human tumors - an antibody raised against human p53 expressed in Escherichia coli. J. Cell Sci. 101:183-189.
45. Midgley, C. A., and D. P. Lane. 1997. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15:1179-1189.
46. Miyashita, T., and J. C. Reed. 1995. Tumor-suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299.
47. Nigro, J. M., S. J. Baker, A. C. Preisinger, J. M. Jessup, R. Hostetter, K. Cleary, S. H. Bigner, N. Davidson, S. Baylin, P. Devilee, T. Glover, F. S. Collins, A. Weston, R. Modali, C. C. Harris, and B. Vogelstein. 1989. Mutations in the p53 gene occur in diverse human tumor types. Nature 342: 705-708.
48. Nip, J., D. K. Strom, G. Zambetti, J. L. Cleveland, and S. W. Hiebert. 1997. E2F-1-mediated induction of p53 in myeloid progenitor cells suppresses topoisomerase II alpha. Blood 90:205.
49. Okamoto, K., and D. Beach. 1994. Cyclin-G is a transcriptional target of the p53 tumor-suppressor protein. EMBO J. 13:4816-4822.
50. Ronca, F., S. L. Chan, and V. C. Yu. 1997. 1-(5-Isoquinolinesulfonyl)-2-methylpiperazine induces apoptosis in human neuroblastoma cells, SH-SY5Y, through a p53-dependent pathway. J. Biol. Chem. 272:4252-4260.
51. Roth, J., M. Dobbelstein, D. Freedmann, T. Shenk, and A. Levine. 1998. Nucleo-cytoplasmic shuttling of the Hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus Rev protein. EMBO J. 17:554-556.
52. Scheffner, M., J. M. Huibregtse, R. D. Vierstra, and P. M. Howley. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505.
53. Shan, B., and W. H. Lee. 1994. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol. Cell. Biol. 14:8166-8173.
54. Sherr, C. J. 1996. Cancer cell cycles. Science 274:1672-1677.
55. Waseem, N. H., and D. P. Lane. 1990. Monoclonal-antibody analysis of the proliferating cell nuclear antigen (PCNA) - structural conservation and the detection of a nucleolar form. J. Cell Sci. 96:121-129.
56. Weinberg, R. A. 1995. The retinoblastoma protein and cell-cycle control. Cell 81:323-330.
57. Wu, L., and A. J. Levine. 1997. Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Mol. Med. 3:441-451.
58. Wu, X. W., J. H. Bayle, D. Olson, and A. J. Levine. 1993. The p53 Mdm-2 autoregulatory feedback loop. Genes Dev. 7:1126-1132.
59. Yamasaki, L., R. Bronson, B. O. Williams, N. J. Dyson, E. Harlow, and T. Jacks. 1998. Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/-) mice. Nat. Genet. 18:360-364.
60. Yamasaki, L., T. Jacks, R. Bronson, E. Goillot, E. Harlow, and N. J. Dyson. 1996. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 85: 537-548.
61. Yankulov, K., K. Yamashita, R. Roy, J. M. Egly, and D. L. Bentley. 1995. The transcriptional elongation inhibitor 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole inhibits transcription factor IIH-associated protein-kinase. J. Biol. Chem. 270:23922-23925.